ERS 2026: AstraZeneca’s IL-33 inhibitor tozorakimab reduces mucus plug burden in COPD
This finding is particularly important as tozorakimab is the first biologic to demonstrate a significant reduction in the number of lung segments with mucus plugs in a broad population.
Unlock FREE Access to Premium Content
Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends.
With a free Pharmaceutical Technology profile, you can:
- Access exclusive analyst commentary and expert insights
- View premium forecasts and data-driven pharmaceutical industry insights
- Stay up to date with pharma news, manufacturing innovation, and regulatory developments
- Receive alerts when new premium content is published
Unlock free access
Already have an account? Login herePowered by
